Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

HRMY

Harmony Biosciences (HRMY)

Harmony Biosciences Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HRMY
DateTimeSourceHeadlineSymbolCompany
05/31/20247:55AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
05/31/20247:52AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
05/29/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HRMYHarmony Biosciences Holdings Inc
05/28/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:HRMYHarmony Biosciences Holdings Inc
04/30/20246:05AMGlobeNewswire Inc.Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare EpilepsyNASDAQ:HRMYHarmony Biosciences Holdings Inc
04/30/20246:00AMPR Newswire (US)Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsNASDAQ:HRMYHarmony Biosciences Holdings Inc
04/16/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024NASDAQ:HRMYHarmony Biosciences Holdings Inc
04/11/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONISTNASDAQ:HRMYHarmony Biosciences Holdings Inc
04/03/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROMENASDAQ:HRMYHarmony Biosciences Holdings Inc
03/26/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCENASDAQ:HRMYHarmony Biosciences Holdings Inc
03/11/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
03/08/20243:21PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/28/20244:16PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:HRMYHarmony Biosciences Holdings Inc
02/28/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/22/20243:14PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/22/20247:00AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HRMYHarmony Biosciences Holdings Inc
02/22/20247:00AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HRMYHarmony Biosciences Holdings Inc
02/22/20246:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/22/20246:30AMGlobeNewswire Inc.Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/21/20247:05AMPR Newswire (US)U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSYNASDAQ:HRMYHarmony Biosciences Holdings Inc
02/20/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROMENASDAQ:HRMYHarmony Biosciences Holdings Inc
02/13/20246:06PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HRMYHarmony Biosciences Holdings Inc
02/08/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024NASDAQ:HRMYHarmony Biosciences Holdings Inc
01/26/20243:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
01/26/20243:58PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
01/26/20243:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
01/26/20243:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRMYHarmony Biosciences Holdings Inc
01/08/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HRMYHarmony Biosciences Holdings Inc
01/08/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCENASDAQ:HRMYHarmony Biosciences Holdings Inc
01/03/20247:05AMPR Newswire (US)HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCENASDAQ:HRMYHarmony Biosciences Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:HRMY